J2353 octreotide - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

octreotide

Brand Name:

sandostatin LAR

Strength:

1 mg

HCPCS:

J2353

SEER*Rx Category:

Hormonal Therapy

Major Drug Class:

Somatostatin Analog

Minor Drug Class:

Oral (Y/N):

No

FDA Approval Year:

1998

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2004

CMS Discontinuation Date:

Status:

In Use